Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth

Oncotarget

Volumn 5, Issue 4, 2014, Pages 1004-1013

  Vindrieux, David ^a,b,c   Devailly, Guillaume ^a,b,c   Augert, Arnaud ^a,b,c   Le Calvé, Benjamin ^a,b,c   Ferrand, Mylène ^a,b,c   Pigny, Pascal ^d,e   Payen, Léa ^a,b,c   Lambeau, Gérard ^f   Perrais, Michael ^d   Aubert, Sébastien ^d,g   Simonnet, Hélène ^a,b,c   Dante, Robert ^a,b,c   Bernard, David ^a,b,c  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITÉ DE LYON   (France)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^g UNIV LILLE   (France)

Author keywords

HIF; MYC; PLA2R1; Tumor suppressor; VHL

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 2ALPHA; MYC PROTEIN; PHOSPHOLIPASE A2 RECEPTOR; SECRETORY PHOSPHOLIPASE A2 RECEPTOR 1; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; MYC PROTEIN, HUMAN; PLA2R1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; CANCER GROWTH; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; ENZYME REPRESSION; GAIN OF FUNCTION MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; UBIQUITINATION; ANIMAL; FEMALE; GENETIC TRANSFECTION; GENETICS; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; HETEROGRAFTS; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, PHOSPHOLIPASE A2; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84897385264     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1681     Document Type: Article

References (33)

1. Lambeau G, Ancian P, Barhanin J and Lazdunski M. Cloning and expression of a membrane receptor for secretory phospholipases A2. J Biol Chem. 1994; 269(3):1575-8.
2. Llorca O. Extended and bent conformations of the mannose receptor family. Cell Mol Life Sci. 2008; 65(9):1302-10.
3. Rouault M, Le Calvez C, Boilard E, Surrel F, Singer A, Ghomashchi F, Bezzine S, Scarzello S, Bollinger J, Gelb MH and Lambeau G. Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry. 2007; 46(6):1647-62.
4. Murakami M, Taketomi Y, Girard C, Yamamoto K and Lambeau G. Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. Biochimie. 2010; 92(6):561-82.
5. Ancian P, Lambeau G and Lazdunski M. Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2. Biochemistry. 1995; 34(40):13146-51.
6. Augert A, Payre C, de Launoit Y, Gil J, Lambeau G and Bernard D. The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep. 2009; 10(3):271-7.
7. Vindrieux D, Augert A, Girard CA, Gitenay D, Lallet-Daher H, Wiel C, Le Calvé B, Gras B, Ferrand M, Verbeke S, de Launoit Y, Leroy X, Puisieux A, et al. PLA2R1 mediates tumor suppression by activating JAK2. Cancer Res. 2013; 73(20):6334-45.
8. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S and Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998; 279(5349):349-52.
9. Vaziri H and Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol. 1998; 8(5):279-82.
10. Adams PD. Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell. 2009; 36(1):2-14.
11. Collado M and Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010; 10(1):51-7.
12. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010 Oct 20;102(20):1536-46.
13. Nardella C, Clohessy JG, Alimonti A and Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer. 2011; 11(7):503-11.
14. Augert A, Vindrieux D, Girard CA, Le Calvé B, Gras B, Ferrand M, Bouchet BP, Puisieux A, de Launoit Y, Simonnet H, Lambeau G and Bernard D. PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radic Biol Med. 2013;65C:969-77.
15. Beck LH, Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB and Salant DJ.. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1):11-21.
16. Kim WY and Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004; 22(24):4991-5004.
17. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5.
18. Shen C and Kaelin WG, Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013; 23(1):18-25.
19. Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S and Kaelin WG Jr. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol. 2007; 27(15):5381-92.
20. Yan Q, Bartz S, Mao M, Li L and Kaelin WG, Jr. The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol. 2007; 27(6):2092-102.
21. Aubert S, Fauquette V, Hemon B, Lepoivre R, Briez N, Bernard D, Van Seuningen I, Leroy X and Perrais M. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res. 2009; 69(14):5707-15.
22. Chatagnon A, Perriaud L, Nazaret N, Croze S, Benhattar J, Lachuer J and Dante R. Preferential binding of the methyl-CpG binding domain protein 2 at methylated transcriptional start site regions. Epigenetics. 2011; 6(11):1295-307.
23. Lau KW, Tian YM, Raval RR, Ratcliffe PJ and Pugh CW. Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br J Cancer. 2007; 96(8):1284-92.
24. Perrin D, Ballestar E, Fraga MF, Frappart L, Esteller M, Guerin JF and Dante R. Specific hypermethylation of LINE-1 elements during abnormal overgrowth and differentiation of human placenta. Oncogene. 2007; 26(17):2518-24.
25. Pavlovich CP and Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer. 2004; 4(5):381-93.
26. Li M and Kim WY. Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med. 2011; 15(2):187-95.
27. Xu J, Wang B, Xu Y, Sun L, Tian W, Shukla D, Barod R, Grillari J, Grillari-Voglauer R, Maxwell PH and Esteban MA. Epigenetic regulation of HIF-1alpha in renal cancer cells involves HIF-1alpha/2alpha binding to a reverse hypoxia-response element. Oncogene. 2012; 31(8):1065-72.
28. Gordan JD, Bertout JA, Hu CJ, Diehl JA and Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007; 11(4):335-47.
29. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC and Nathanson KL. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008; 14(6):435-46.
30. Brenner C, Deplus R, Didelot C, Loriot A, Vire E, De Smet C, Gutierrez A, Danovi D, Bernard D, Boon T, Pelicci PG, Amati B, Kouzarides T, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. Embo J. 2005; 24(2):336-46.
31. Kleine-Kohlbrecher D, Adhikary S and Eilers M. Mechanisms of transcriptional repression by Myc. Curr Top Microbiol Immunol. 2006; 302:51-62.
32. Menschikowski M, Platzbecker U, Hagelgans A, Vogel M, Thiede C, Schonefeldt C, Lehnert R, Eisenhofer G and Siegert G. Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells. BMC Cancer. 2012; 12:576.
33. Keith B, Johnson RS and Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012; 12(1):9-22.